HK Inno.N

HK Inno.N Inventory

The Inventory of HK Inno.N (195940.KQ) as of Nov 3, 2026 is 168.14 B KRW. In the previous year, Inventory was 177.40 B KRW — a change of -5.22% (lower).

Inventory

168.14 BKRW

YoY

-5.22%

Last updated:

Inventory of HK Inno.N is 2025 168.14 B KRW. Inventory of HK Inno.N was 2024 177.40 B KRW. It decreases by -5.22% lower compared to the previous year.

The HK Inno.N Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
51.77 B KRW
Jan 1, 2019
57.11 B KRW
Jan 1, 2020
77.91 B KRW
Jan 1, 2021
108.64 B KRW
Jan 1, 2022
125.84 B KRW
Jan 1, 2023
141.68 B KRW
Jan 1, 2024
177.40 B KRW
Jan 1, 2025
168.14 B KRW
The HK Inno.N Inventory history
YEARInventoryYoY
168.14 BKRW-5.22%
177.40 BKRW+25.21%
141.68 BKRW+12.59%
125.84 BKRW+15.84%
108.64 BKRW+39.44%
77.91 BKRW+36.42%
57.11 BKRW+10.31%
51.77 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

HK Inno.N Stock analysis

What does HK Inno.N do? HK inno.N Corp. generates revenue through its Prescription Drug segment, which manufactures and sells hormone drugs, anticancer drugs, high blood pressure drugs, gastroesophageal reflux disease drugs, blood nutrient supplies, and circulatory system products. The Health Beauty and Beverage (HB&B) segment contributes by producing and distributing hangover relieving products, health drinks, and food items. The Other segment earns income from trademark royalties and additional services. Products are sold domestically and internationally, targeting healthcare consumers and businesses seeking pharmaceutical and wellness solutions. The company's Prescription Drug segment focuses on specialized medical treatments, while HB&B targets health-conscious consumers with lifestyle products. Trademark royalties in the Other segment provide supplementary revenue from intellectual property licensing. Domestic sales form a significant portion of the business, with international markets expanding the company's reach. HK inno.N Corp. serves healthcare providers and end consumers through its Prescription Drug segment, with products like anticancer and high blood pressure drugs. HB&B products such as hangover relievers and health drinks cater to individual wellness needs. The Other segment’s trademark royalties support brand value, with sales spanning both local and global markets. HK Inno.N is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HK Inno.N stock

Inventory of HK Inno.N is 168.14 B KRW in 2025.

Inventory of HK Inno.N changed from 177.40 B KRW to 168.14 B KRW, representing a -5.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Inventory HK Inno.N since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's HK Inno.N historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — HK Inno.N

All Key Metrics — HK Inno.N